Literature DB >> 21951710

The development and psychometric validation of the central sensitization inventory.

Tom G Mayer1, Randy Neblett, Howard Cohen, Krista J Howard, Yun H Choi, Mark J Williams, Yoheli Perez, Robert J Gatchel.   

Abstract

Central sensitization (CS) has been proposed as a common pathophysiological mechanism to explain related syndromes for which no specific organic cause can be found. The term "central sensitivity syndrome (CSS)" has been proposed to describe these poorly understood disorders related to CS. The goal of this investigation was to develop the Central Sensitization Inventory (CSI), which identifies key symptoms associated with CSSs and quantifies the degree of these symptoms. The utility of the CSI, to differentiate among different types of chronic pain patients who presumably have different levels of CS impairment, was then evaluated. Study 1 demonstrated strong psychometric properties (test-retest reliability = 0.817; Cronbach's alpha = 0.879) of the CSI in a cohort of normative subjects. A factor analysis (including both normative and chronic pain subjects) yielded 4 major factors (all related to somatic and emotional symptoms), accounting for 53.4% of the variance in the dataset. In Study 2, the CSI was administered to 4 groups: fibromyalgia (FM); chronic widespread pain without FM; work-related regional chronic low back pain (CLBP); and normative control group. Analyses revealed that the patients with FM reported the highest CSI scores and the normative population the lowest (P < 0.05). Analyses also demonstrated that the prevalence of previously diagnosed CSSs and related disorders was highest in the FM group and lowest in the normative group (P < 0.001). Taken together, these 2 studies demonstrate the psychometric strength, clinical utility, and the initial construct validity of the CSI in evaluating CS-related clinical symptoms in chronic pain populations. Published 2011. No claim to original US government works. Pain Practice
© 2011 World Institute of Pain.

Entities:  

Mesh:

Year:  2011        PMID: 21951710      PMCID: PMC3248986          DOI: 10.1111/j.1533-2500.2011.00493.x

Source DB:  PubMed          Journal:  Pain Pract        ISSN: 1530-7085            Impact factor:   3.183


  74 in total

1.  Risk factors predicting the development of widespread pain from chronic back or neck pain.

Authors:  Lindsay L Kindler; Kim D Jones; Nancy Perrin; Robert M Bennett
Journal:  J Pain       Date:  2010-05-21       Impact factor: 5.820

2.  The Symptom Intensity Scale, fibromyalgia, and the meaning of fibromyalgia-like symptoms.

Authors:  Frederick Wolfe; Johannes J Rasker
Journal:  J Rheumatol       Date:  2006-09-01       Impact factor: 4.666

3.  Validation of the Japanese version of comorbid conditions questionnaire (CCQ-J) and recent physical symptoms questionnaire (RPSQ-J).

Authors:  Masae Shinozaki; Motoyori Kanazawa; Olafur S Palsson; Yasuhiro Sagami; Yuka Endo; Michio Hongo; Douglas A Drossman; William E Whitehead; Shin Fukudo
Journal:  Intern Med       Date:  2011-03-01       Impact factor: 1.271

4.  Psychosocial factors in fibromyalgia compared with rheumatoid arthritis: I. Psychiatric diagnoses and functional disability.

Authors:  E A Walker; D Keegan; G Gardner; M Sullivan; W J Katon; D Bernstein
Journal:  Psychosom Med       Date:  1997 Nov-Dec       Impact factor: 4.312

5.  Increased rates of fibromyalgia following cervical spine injury. A controlled study of 161 cases of traumatic injury.

Authors:  D Buskila; L Neumann; G Vaisberg; D Alkalay; F Wolfe
Journal:  Arthritis Rheum       Date:  1997-03

6.  Etiopathogenetic mechanisms of fibromyalgia syndrome.

Authors:  S Stisi; M Cazzola; D Buskila; M Spath; M A Giamberardino; P Sarzi-Puttini; G Arioli; A Alciati; G Leardini; R Gorla; A Marsico; F Ceccherelli; L Bazzichi; R Carignola; R H Gracely; F Salaffi; F Marinangeli; R Torta; M Di Franco; G Biasi; G Cassisi; R Casale; L Altomonte; F Atzeni
Journal:  Reumatismo       Date:  2008 Jul-Sep

7.  Cognitive impairment in patients with fibromyalgia syndrome as assessed by the mini-mental state examination.

Authors:  Jose Rodríguez-Andreu; Rosario Ibáñez-Bosch; Amparo Portero-Vázquez; Xavier Masramon; Javier Rejas; Rafael Gálvez
Journal:  BMC Musculoskelet Disord       Date:  2009-12-21       Impact factor: 2.362

8.  Psychiatric status of patients with primary fibromyalgia, patients with rheumatoid arthritis, and subjects without pain: a blind comparison of DSM-III diagnoses.

Authors:  T A Ahles; S A Khan; M B Yunus; D A Spiegel; A T Masi
Journal:  Am J Psychiatry       Date:  1991-12       Impact factor: 18.112

9.  Patients treated by tegaserod for irritable bowel syndrome with constipation showed significant improvement in fibromyalgia symptoms. A pilot study.

Authors:  Tatiana Reitblat; Doron Zamir; Ilia Polishchuck; Galina Novochatko; Stephen Malnick; Leonid Kalichman
Journal:  Clin Rheumatol       Date:  2009-05-26       Impact factor: 2.980

10.  Major depression, fibromyalgia and labour force participation: a population-based cross-sectional study.

Authors:  Aliya Kassam; Scott B Patten
Journal:  BMC Musculoskelet Disord       Date:  2006-01-19       Impact factor: 2.362

View more
  133 in total

1.  New perspectives on dry needling following a medical model: are we screening our patients sufficiently?

Authors:  Gary Kearns; César Fernández-De-Las-Peñas; Jean-Michel Brismée; Josué Gan; Jacqueline Doidge
Journal:  J Man Manip Ther       Date:  2019-01-19

2.  The mediating effect of pain catastrophizing and perceived injustice in the relationship of pain on health-related quality of life in breast cancer survivors.

Authors:  Laurence Leysen; Wilfried Cools; Jo Nijs; Nele Adriaenssens; Roselien Pas; C Paul van Wilgen; Rinske Bults; Eva Roose; Astrid Lahousse; David Beckwée
Journal:  Support Care Cancer       Date:  2021-02-10       Impact factor: 3.603

Review 3.  Does central sensitization help explain idiopathic overactive bladder?

Authors:  W Stuart Reynolds; Roger Dmochowski; Alan Wein; Stephen Bruehl
Journal:  Nat Rev Urol       Date:  2016-06-01       Impact factor: 14.432

4.  The important role of central sensitization in chronic musculoskeletal pain seen in different rheumatic diseases.

Authors:  Mehmet Akif Guler; Omer Faruk Celik; Fikriye Figen Ayhan
Journal:  Clin Rheumatol       Date:  2019-08-24       Impact factor: 2.980

5.  Posttraumatic Stress Symptoms Mediate the Effects of Trauma Exposure on Clinical Indicators of Central Sensitization in Patients With Chronic Pain.

Authors:  Lindsey C McKernan; Benjamin N Johnson; Leslie J Crofford; Mark A Lumley; Stephen Bruehl; Jennifer S Cheavens
Journal:  Clin J Pain       Date:  2019-05       Impact factor: 3.442

Review 6.  Toward a Mechanism-Based Approach to Pain Diagnosis.

Authors:  Daniel Vardeh; Richard J Mannion; Clifford J Woolf
Journal:  J Pain       Date:  2016-09       Impact factor: 5.820

Review 7.  Explaining pain following cancer: a practical guide for clinicians.

Authors:  Jo Nijs; Amarins J Wijma; Laurence Leysen; Roselien Pas; Ward Willaert; Wouter Hoelen; Kelly Ickmans; C Paul van Wilgen
Journal:  Braz J Phys Ther       Date:  2018-12-21       Impact factor: 3.377

8.  Foot pain severity is associated with the ratio of visceral to subcutaneous fat mass, fat-mass index and depression in women.

Authors:  Tom P Walsh; John B Arnold; Tiffany K Gill; Angela M Evans; Alison Yaxley; Catherine L Hill; E Michael Shanahan
Journal:  Rheumatol Int       Date:  2017-05-17       Impact factor: 2.631

9.  The Central Sensitization Inventory (CSI): establishing clinically significant values for identifying central sensitivity syndromes in an outpatient chronic pain sample.

Authors:  Randy Neblett; Howard Cohen; YunHee Choi; Meredith M Hartzell; Mark Williams; Tom G Mayer; Robert J Gatchel
Journal:  J Pain       Date:  2013-03-13       Impact factor: 5.820

10.  Posttraumatic stress disorder in interstitial cystitis/bladder pain syndrome: Relationship to patient phenotype and clinical practice implications.

Authors:  Lindsey C McKernan; Benjamin N Johnson; William S Reynolds; David A Williams; Jennifer S Cheavens; Roger R Dmochowski; Leslie J Crofford
Journal:  Neurourol Urodyn       Date:  2018-10-23       Impact factor: 2.696

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.